Skip to main content
. 2013 Aug 30;2013(8):CD001245. doi: 10.1002/14651858.CD001245.pub2

Fodstad 1981.

Methods Single‐centre study
 Random allocation (identical sequentially numbered sealed envelope)
 No blind treatment
 Not strictly ITT: 1 of the 30 control participants was excluded after randomisation because he had received tranexamic acid before admission
Participants Clinical diagnosis of aneurysmal SAH verified with CSF, CT scan and angiography
 Male:female: treatment group 13:17; control group 12:17
 Mean age: treatment group 50 years (range 19 to 72); control group 53 years (range 27 to 70)
 Excluded: SAH > 3 days and known thrombotic disease
Interventions Tranexamic acid (6 g per day iv in 6 doses during the first week, 4 g in 4 doses iv in week 2 and 6 g orally in 4 doses in week 3 to 6) for a maximum duration of 6 weeks versus control group. Treatment continued until rebleeding, operation, discharge or death
Outcomes Outcome: deaths from all causes at 6‐week follow‐up
 Events: rebleeding: reported, confirmed by CSF examination/spectrophotometry, CT‐scan or at necropsy; cerebral ischaemia: reported, not defined; hydrocephalus: reported, not defined
Notes Of the participants with rebleeding, 5 of 6 in the treatment group and 5 of 7 in the control group died. All had necropsy. In the remaining participants rebleeding was confirmed by CT. 6 of 8 participants with cerebral ischaemia in the treatment group and 2 of 3 in the control group died. All had necropsy, in the remaining participants cerebral ischaemia was established on CT
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not described in the text
Allocation concealment (selection bias) Unclear risk "Patients were assigned randomly" and "the sealed envelope technique was used"
 It was not mentioned whether these envelopes were opaque or not
Blinding of participants and personnel (performance bias) 
 All outcomes High risk Participants and personnel were not blinded (open study)
Blinding of outcome assessment (detection bias) 
 All outcomes High risk Part of recurrent haemorrhages were confirmed by lumbar puncture
Incomplete outcome data (attrition bias) 
 All outcomes Low risk 1 participant was excluded from final analysis
Selective reporting (reporting bias) Low risk Protocol was previously published
Other bias Low risk None suspected based on study design and outcome